

Jeffrey R Infante

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11573039/publications.pdf>

Version: 2024-02-01

93
papers

10,539
citations

66315

42
h-index

45285

90
g-index

94
all docs

94
docs citations

94
times ranked

16113
citing authors

#	ARTICLE	IF	CITATIONS
1	Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. <i>Lancet, The</i> , 2012, 379, 1893-1901.	6.3	856
2	Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, in Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2117-2124.	0.8	538
3	Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 833-842.	0.8	517
4	Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. <i>Lancet Oncology, The</i> , 2018, 19, 51-64.	5.1	491
5	Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. <i>Lancet Oncology, The</i> , 2012, 13, 773-781.	5.1	487
6	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. <i>Lancet Oncology, The</i> , 2012, 13, 782-789.	5.1	479
7	Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2013, 31, 482-489.	0.8	439
8	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3851-3858.	0.8	384
9	Peritumoral Fibroblast SPARC Expression and Patient Outcome With Resectable Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 319-325.	0.8	372
10	Targeting CDK4/6 in patients with cancer. <i>Cancer Treatment Reviews</i> , 2016, 45, 129-138.	3.4	356
11	Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3401-3408.	0.8	324
12	Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2 Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 867-874.	0.8	290
13	A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. <i>European Journal of Cancer</i> , 2014, 50, 2072-2081.	1.3	283
14	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. <i>Cancer Discovery</i> , 2018, 8, 184-195.	7.7	283
15	Overall Survival and Durable Responses in Patients With BRAF V600E-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 871-878.	0.8	266
16	Molecular Pathways: Fatty Acid Synthase. <i>Clinical Cancer Research</i> , 2015, 21, 5434-5438.	3.2	212
17	Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2012, 30, 1527-1533.	0.8	204
18	Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 3562-3569.	0.8	175

#	ARTICLE	IF	CITATIONS
19	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With <i>BRAF</i> ^{V600} -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2014, 32, 3697-3704.	0.8	173
20	PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. <i>Cancer Cell</i> , 2018, 34, 775-791.e3.	7.7	170
21	Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). <i>Clinical Cancer Research</i> , 2013, 19, 4868-4878.	3.2	167
22	Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma. <i>Cell Reports</i> , 2013, 4, 1090-1099.	2.9	162
23	Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2014, 32, 3103-3110.	0.8	160
24	Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations. <i>Clinical Cancer Research</i> , 2012, 18, 4775-4784.	3.2	141
25	Targeting PI3 kinase in cancer. , 2015, 146, 53-60.		129
26	Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly <i>nab-<i>I</i></i> Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. <i>Oncologist</i> , 2015, 20, 143-150.	1.9	123
27	A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 1100-1107.	1.2	121
28	Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2017, 35, 2028-2036.	0.8	111
29	Accumulation of Extracellular Hyaluronan by Hyaluronan Synthase 3 Promotes Tumor Growth and Modulates the Pancreatic Cancer Microenvironment. <i>BioMed Research International</i> , 2014, 2014, 1-15.	0.9	99
30	Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies. <i>Drugs</i> , 2014, 74, 1993-2013.	4.9	96
31	Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1544-1555.	5.1	86
32	Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. <i>Cancer</i> , 2018, 124, 2010-2017.	2.0	81
33	Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 1133-1142.	5.1	76
34	A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. <i>European Journal of Cancer</i> , 2016, 56, 1-9.	1.3	76
35	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i> . <i>Clinical Cancer Research</i> , 2021, 27, 5236-5247.	3.2	74
36	A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. <i>British Journal of Cancer</i> , 2017, 116, 575-583.	2.9	73

#	ARTICLE	IF	CITATIONS
37	Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2014, 32, 4504-4504.	0.8	73
38	A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. European Journal of Cancer, 2013, 49, 2077-2085.	1.3	72
39	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 30.		68
40	Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biology and Therapy, 2007, 6, 1569-1575.	1.5	63
41	Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2011, 67, 945-954.	1.1	63
42	Clinical responses to selumetinib (AZD6244;ARRY42886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer, 2013, 119, 799-805.	2.0	63
43	Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research, 2014, 20, 4449-4458.	3.2	56
44	Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. British Journal of Cancer, 2018, 118, 153-161.	2.9	51
45	Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase 1b JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. , 2020, 8, e001246.		49
46	Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors.. Journal of Clinical Oncology, 2015, 33, 2512-2512.	0.8	45
47	Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase. Cancer Research, 2011, 71, 675-685.	0.4	43
48	A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors. Investigational New Drugs, 2016, 34, 216-224.	1.2	42
49	A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas.. Journal of Clinical Oncology, 2014, 32, 2528-2528.	0.8	42
50	Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 70, 699-705.	1.1	41
51	A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 556-566.	0.5	40
52	Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors. Journal of Pharmaceutical Sciences, 2013, 102, 3100-3109.	1.6	39
53	Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors. Oncologist, 2010, 15, 1253-1261.	1.9	38
54	Assessment of the drug interaction potential and single and repeat dose pharmacokinetics of the BRAF inhibitor dabrafenib. Journal of Clinical Pharmacology, 2015, 55, 392-400.	1.0	37

#	ARTICLE	IF	CITATIONS
55	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. <i>Investigational New Drugs</i> , 2015, 33, 652-663.	1.2	35
56	Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1820-1828.	1.9	34
57	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/II trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8028-8028.	0.8	28
58	Successful Treatment With Dabrafenib (GSK2118436) in a Patient With Ganglioglioma. <i>Journal of Clinical Oncology</i> , 2014, 32, e98-e100.	0.8	27
59	Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 167-167.	0.8	27
60	Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 367-367.	0.8	26
61	Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 2624-2634.	3.2	25
62	A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer. <i>European Journal of Cancer</i> , 2011, 47, 199-205.	1.3	24
63	Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of MEK344 as a single agent in patients with refractory solid tumors. <i>Cancer</i> , 2015, 121, 1056-1063.	2.0	24
64	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/II trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8027-8027.	0.8	22
65	Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2530-2530.	0.8	19
66	Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3044-3044.	0.8	18
67	Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4005-4005.	0.8	18
68	A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2585-2585.	0.8	17
69	Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 2073-2081.	0.8	16
70	Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. <i>International Journal of Nanomedicine</i> , 2015, 10, 1201.	3.3	16
71	BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naïve and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9005-9005.	0.8	16
72	Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial. <i>Cancer Biology and Therapy</i> , 2013, 14, 340-346.	1.5	13

#	ARTICLE	IF	CITATIONS
73	Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with <i>BRAF</i> V600â€ mutant tumours. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 764-775.	1.1	13
74	A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors. <i>BMC Cancer</i> , 2017, 17, 173.	1.1	12
75	Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2503-2503.	0.8	12
76	Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 287-294.	0.8	11
77	A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 137-144.	1.1	10
78	A five-arm, open-label, phase I/IIb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3023-3023.	0.8	10
79	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: Safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3055-3055.	0.8	10
80	A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 87-93.	1.2	9
81	Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). <i>Investigational New Drugs</i> , 2021, 39, 182-192.	1.2	8
82	A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with nonâ~ small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2507-2507.	0.8	8
83	Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4059-4059.	0.8	6
84	CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4058-4058.	0.8	5
85	A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4593-TPS4593.	0.8	5
86	Overall survival of PEGylated pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4119-4119.	0.8	5
87	Circulating cytokines and angiogenic factors (CAF) as markers of clinical response in the study of trametinib (T) plus gemcitabine (G) versus placebo (P) plus gemcitabine for patients (pts) with untreated metastatic adenocarcinoma of the pancreas (MEK113487).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4042-4042.	0.8	3
88	Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3564-3564.	0.8	2
89	Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9066-9066.	0.8	1
90	A phase I/IIb study of paclitaxel in combination with VS-6063, a focal adhesion kinase (FAK) inhibitor, in patients (pts) with advanced ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS2620-TPS2620.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Results of two phase I dose escalation studies of the oral heat shock protein 90 (Hsp90) inhibitor SNX-5422.. Journal of Clinical Oncology, 2013, 31, 2617-2617.	0.8	1
92	A community-based program for personalized cancer care using next-generation sequencing (NGS).. Journal of Clinical Oncology, 2013, 31, 11102-11102.	0.8	1
93	Phase I study of c-Met inhibitor ARQ197 in combination with FOLFOX for the treatment of patients with advanced solid tumors.. Journal of Clinical Oncology, 2013, 31, 2544-2544.	0.8	0